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given as radical or adjuvant treatment for PC in 4 and 5 
patients respectively and as neoadjuvant therapy for rectal 
cancer in 1 case. The median dose of prior RT was 70 Gy 
(range 45-76) and the median time between the first and the 
second RT course was 117 months (range 95-219). The total 
dose of retreatment was 50 Gy in 5 patients and 60 Gy in 2 (2 
Gy daily fraction). Patients immobilized with Combifix device 
underwent planning computed tomography (CT) with 3-mm 
slice thickness; they were instructed to receive RT every day 
with an empty rectum and a full bladder. Clinical target 
volume (CTV) was the prostate in 5 and the PET positive 
nodule in 2 patients. Organs at risk (OAR) were: rectum, 
bladder, penile bulb and femoral heads. Planning target 
volume (PTV) was obtained by adding 3-5 mm to the 
corresponding CTV. The parameters used in HT planning 
system were: field width 1 or 2.5 cm, pitch 0.287 and 
modulation factor ranging from 2 to 3. Median duration of 
treatments was 180.7 seconds (range 145-347.8). 
Results: Median follow up was 7 months (range 3-38). All 
patients completed the reirradiation course. PTV median size 
was 66.65 cc (range 7.91 – 114.26). The cumulative mean 
dose (D mean) to the rectum ranged from 37.87 to 73.83 Gy 
and the cumulative rectal maximum dose (D max) ranged 
from 112.66 to 119.85 Gy. The cumulative D mean to the 
bladder ranged between 19.84 and 83.79 Gy; cumulative D 
max ranged from 93.99 to 126.3 Gy. When total dose was 50 
Gy, the OAR dose volume constraints were: V10< 40% and 
V25<10% for rectum; V10<20%, V25<10% and V44<2% for 
bladder. When total dose was 60 Gy the constraints were: 
V10<30% and V30<1% for rectum and V10<15%, V30<10% and 
V50<5% for bladder. Acute grade 2 genitourinary toxicity was 
observed in 3 patients and grade 2 gastrointestinal toxicity in 
1 patient. Three months after retreatment all patients had 
early PSA decrease; only 2 patients experienced biochemical 
relapse due to pelvic nodal recurrence. One patient died for 
bladder cancer.  
Conclusions: PC patients benefit from salvage reirradiation 
with HT. The treatment was feasible and well tolerated, with 
low rates of acute toxicity. Longer follow up is required to 
confirm retreatment safety and evaluate late toxicity. 
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Purpose/Objective: Even if many advances have been done 
in cancer care, clinical choices are based on evidence-based 
guidelines, resulted from large randomized trials often, and 
applicable only to population subset. Need of 'tailored 
treatment' can require specialized Decision Support System 
(DSS). Therefore, creation of large, and heterogeneous 
databases, could implement and validate DSS based on 
predictive models. In order to share the same meaning 
between people involved in the project, an ontology need to 
be created and shared. Our aim is to build a prostate cancer 
ontology able to represent a list of the main concepts 
involved in this semantic domain and how those concepts are 
related, by a graph. 
Materials and Methods: We built ontology starting from a 
well-defined data collection model, able to collect, 
standardize and organize concepts related with prostate 
cancer patients. These features were organized according 
three different levels. The first, Registry level, includes all 
general epidemiological information (age, gender, e.g.). The 
second, Procedure tier, includes information about treatment 
and toxicities, and outcome evaluation. The last, Research 
level, includes clinical, imaging and Quality of Life 
information for advanced research projects. Relationships 
between concepts have been added as last step. The so built 
ontology describes each of these concepts with a unique 
reference, preferably mapped to a published coding system 
(e.g. NCI Thesaurus, CTCAE).  
Results: Building an ontology is a good strategy to 
standardize data and procedure and create a consistent 
dataset. We selected more than 200 variables related with 
prostate cancer. The three data storing tiers were used to 
classify all the information to easily develop queries 
depending on the analysis different (epidemiological, 
toxicity, outcomes e.g.). Many concepts can be shared with 
ontologies related other cancer sites (general idea of 
toxicities, TNM, etc.) while others are prostate specific (PSA, 
etc.). We decided to adopt a trade-off between the formal 
explication of the ontology and the effective usability of it: 
even if a formal ontology is a powerful tool to allow 
automatic inference and represent in a not-ambiguous way a 
semantic, it is hard to be handled and properly validated.  
Conclusions: Sharing and combining multiple dataset, 
through structural collaboration between different groups, 
are the basis to generate large databases. Computer Science 
allows us to share concepts in a not ambiguous way in order 
to do that, by using ontologies and related languages. 
Through an ontology creation we obtained a standardized and 
organized dataset, easy to be shared and understood, not 
ambiguous, mapped on most common international standards 
and suitable to create predictive models which complement 
existing consensus or guidelines, moving from prescription by 
consensus to prescription by numbers.  
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Purpose/Objective: The aim of this study is to evaluate the 
changes in bladder doses during the volumetric modulated 
arc therapy (VMAT) treatment of prostate cancer patients 
using weekly cone beam computed tomography (CBCT) data. 
Materials and Methods: Ten consecutive patients with 
prostate cancer treated by radical RT were considered. For 
each patient, pre-treatment CBCT performed on a weekly 
basis were analyzed by using two different methods of target 
localization (intraprostatic fiducials and bony anatomy). To 
evaluate the changes in bladder doses; organs of interest 
were contoured on each weekly treatment CBCT data set and 
the images, along with the contours, were registered to the 
original planning CT. The replanning was made on planning 
CT using contours transfered from CBCT for two different 
S678                                                                                                                                         3rd ESTRO Forum 2015 
 
positioning methods. The doses received by 20%, 40% and 50% 
volume of bladder were compared to those of the original 
treatment plans. 
Results: Based on contours from CBCT images, for bony 
anatomy positioning method the delivered bladder doses 
were on average 591.7 cGy (± 276), 413.6 cGy (± 178), 367.4 
cGy (± 93) lower than the planned dose for D20%, D40%, D50% 
respectively. For fiducial positioning method, they were 
141.2 cGy (± 84), 82.2 cGy (± 61), 67.3 cGy (± 47) lower than 
the planned dose respectively. The dose difference between 
planned and delivered dose shows that the greatest variation 
depending on the bladder filling among the fractions. 
Although, significant differences in bladder volumes and 
subsequent increases in dose were observed in two out of ten 
patients, the bladder doses are still within the acceptance 
criteria. Results indicate a wide range in bladder doses 
throughout treatment, which partly depends on the methods 
used for patient positioning. Of the two patient positioning 
methods evaluated, the least amount of bladder dose 
variability, is seen when target localization was made using 
intraprostatic fiducials. 
Conclusions: Large interfraction variations in bladder filling 
hamper accurate radiotherapy of prostate cancer. Although 
the reproducibility of bladder filling during treatment is low, 
since the estimated mean bladder volume is generally larger 
when compared with the value at the planning CT scan, the 
bladder doses are within the tolerance limits. 
    
EP-1254   
Proctoscopic evaluation of rectal toxicity after radio-
hormone therapy in prostate cancer 
 
A. Galuppi1, F. Deodato2, E. Shukulli1, E. Ippolito3, C. Digesù2, 
L. Tagliaferri4, G. Macchia2, S. Cammelli1, V. Valentini4, A.G. 
Morganti1 
1Policlinico Universitario S. Orsola-Malpighi, Radiotherapy 
Department, Bologna, Italy  
2Fondazione 'Giovanni Paolo II' Catholic University of Sacred 
Heart, Radiation Oncology Unit, Campobasso, Italy  
3Campus Biomedico University, Radiation Oncology Unit, 
Roma, Italy  
4Catholic University of Sacred Heart, Radiation Oncology 
Unit, Roma, Italy  
 
Purpose/Objective: Late rectal toxicity is one of the most 
important negative consequencies of radiation therapy in 
patients with prostatic carcinoma (CAP). In a previous study 
we observed a significant correlation between proctoscopy 
outcome one year after RT and late rectal toxicity during the 
follow-up. Therefore we proposed early proctoscopy as a 
surrogate end-point for late rectal toxicity. Aim of this study 
was to investigate predictive factors of late rectal toxicity by 
proctoscopy. 
Materials and Methods: The analysis included all patients 
who underwent proctoscopy one year after the end of 
radiation therapy. Proctoscopy was performed by the same 
operators, using Wachter score. The following parameters 
were analyzed as potential predictive factors: RT dose, 
fractionation, pelvic lymph nodes irradiation, previous 
prostatectomy, timing and type of hormone therapy. 
Statistical analysis was performed using the chi-square test 
(univariate analysis) and logistic model (multivariate 
analysis). 
Results: In this analysis 157 patients with non metastatic CAP 
treated with curative and adjuvant RT were included. 
The results are shown in the table below. 
 
Conclusions: In a proctoscopy evaluation of radiation-
induced rectal toxicity only patients who underwent adjuvant 
hormonal therapy based on LH-RH- analogues, showed a 
trend to a higher risk of toxicity. The lack of correlation with 
other clinical parameters can be partially explained by the 
use of SIB-based modulated techniques (IMR-VMAT) in 
patients treated with hypofractionated RT. 
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Purpose/Objective: MR imaging following needle 
implantation in high dose rate brachytherapy (HDR BT) 
provide more anatomical details for improved definition of 
the prostate gland, organs at risk, and needles. The purpose 
of this study was to evaluate the introduction of MRI guided 
HDR BT, including time consumption, dose volume 
parameters, and changes over time.  
Materials and Methods: A team of radiation oncologists, 
physicists, radiologists, and nurses was trained to perform 
MRI guided HDR BT. Between September 2012 and November 
2014, 42 consecutive high risk prostate cancer patients 
received two times HDR BT of each 8.5 Gy after EBRT. Time 
was recorded for initiation of anaesthesia, end of ultrasound 
guided needle implantation, MR scan, and HDR BT delivery. 
We defined implantation time as duration from initiation of 
anaesthesia to end of needle implantation, and total 
procedure time as duration from initiation of anaesthesia to 
end of HDR BT delivery. Dose volume parameters were 
retrieved from the dose planning system. 
Results: Implantation time was reduced from an initial level 
of ~4.5 hours min to ~2.5 hours at ~800 days from 
introduction. Implantation time at the second HDR BT 
procedure was in average 12 min faster than the first. Total 
procedure time was reduced from an initial level of ~10 hours 
min to ~5 hours min at ~800 days from introduction. Total 
procedure time of the second HDR BT was in average 17 min 
faster than the first. Estimated extra time consumption of 
the post implant MRI was median 66 min (range 26-195 min). 
